Fig. 2

Patient disposition in the cross-sectional phase and the longitudinal phase. ^aEleven patients did not have device assessment because training devices were not available at the site. Withdrawals during the cross-sectional phase were not captured because of the study design. ^bOne patient was eligible for the longitudinal phase and was included in the ITT analysis; however, no device was available at the visit and the patient withdrew consent before treatment was allocated. ^cOnly patients who achieved device mastery on both devices could proceed to stage 2. ^dData were captured retrospectively. ^eOther reasons for study withdrawal during the longitudinal phase included the following: Visit 2 was not scheduled and patient inclusion/exclusion criteria were not met. Note: Numbers in parentheses are numbers of patients. Percentages are based on the number of patients randomly assigned device order in the cross-sectional phase (n = 493). BF: budesonide formoterol; FAS: full analysis set; ITT: intent-to-treat